This World Kidney Day, join hundreds around the globe in kidney disease prevention
World Kidney Day was created to raise awareness and education about the importance of kidney health. This year, the World Kidney Day campaign aims to achieve kidney health for everyone, everywhere. With point-of-care testing, primary healthcare providers can do just that and more — in minutes.
Early screening is the most powerful tool against a powerful disease.
Kidney disease is one of the most serious complications of diabetes. When your kidneys are damaged by diabetes and/or high blood pressure, they’re less able to work effectively.
Kidney disease has no tell-tale warning signs. In fact, a person can lose up to 90% of their kidney functions before experiencing any warning signs.1 That’s why the American Diabetes Association (ADA) recommends annual screening — especially with at-risk patients. Global studies point to obesity, hypertension, diabetes, hyperlipidemia and smoking as the biggest risk factors.2
The good news is, identifying renal disease early — and monitoring it consistently — can make all the difference.
Early detection is key on World Kidney Day — and every other day.
Rapid point-of-care testing such as Abbott’s Afinion™ ACR assay enable healthcare providers to detect and treat kidney disease in minutes. Measuring ACR increases the accuracy compared to urine albumin only. ACR is the recommended method by ADA and NKF to determine albuminuria.
By combining immediate treatment with the necessary lifestyle changes — such as maintaining blood glucose, blood pressure and cholesterol levels — many people with diabetes are able to delay the onset of complications — or prevent them altogether.3
Accurate, fast and simple to use, they help patients better manage their diabetes and prevent costly medical events in the future.
Immediate results mean immediate advice
People with diabetes and hypertension are at a significantly higher risk of developing kidney damage. Identifying and monitoring renal disease in patients with diabetes and hypertension can make all the difference — and Abbott makes it fast and easy with a compact rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care.
Highly-accurate results in 5 minutes
Part of a multi-assay system, the Afinion™ ACR helps you test for quantitative determination of albumin, creatinine and albumin/creatinine ratio (ACR) in human urine. This test is used with patients who have chronic conditions, such as diabetes and hypertension, to detect kidney disease at an early stage.
Short assay time in 3 minutes
The CLIA-waived Afinion™ HbA1c test gives you reliable lab quality results conveniently available when and where you need them. This test is used for quantitative determination of glycated hemoglobin (HbA1c) in human whole blood, used to monitor metabolic control in patients with diabetes. It also provides the immediate test results you need for improved diabetic control, better patient outcomes, and enhanced clinic efficiencies.
Accurate, actionable results from the leader in point-of-care lipid testing
Used in thousands of physician offices, hospitals and wellness programs nationwide, the CLIA-waived Alere Cholestech LDX® System helps monitor your at-risk patients. Engineered for confidence, this analyzer provides accurate, actionable, and readily accessible results for point-of-care lipid profile and glucose testing.
Did you know…
“It is recommended that urinary albumin excretion should be measured in persons at future risk of CVD or renal disease, regardless of whether they have diabetes or not.”
~ Trond Jenssen, MD, PhD, Professor of Medicine.